Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

D. L. Richardson, F. J. Backes, J. D. Hurt, L. G. Seamon, L. J. Copeland, J. M. Fowler, D. E. Cohn, D. M. O'Malley

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background.: Increased rates of bowel perforation in patients with recurrent epithelial ovarian cancer (EOC) treated with bevacizumab have been reported, but the risk factors for this association are uncertain. We sought to identify factors associated with bowel perforation and fistula formation in recurrent EOC patients treated with bevacizumab. Methods.: A chart review of all patients treated with bevacizumab for recurrent EOC at a single institution was performed. Pertinent patient characteristics and treatment information were collected. Univariate logistic regression was performed to analyze multiple variables. Results.: One hundred twelve patients who were treated with 160 different bevacizumab regimens were identified. The median age was 60 years (range, 29-78 years). Patients had received a median of 4 prior chemotherapy regimens (range, 1-10). The median number of cycles was 4 (range, 0.5-31). Ten patients (9%) were diagnosed with bowel perforations, and another 2 patients (1.8%) were diagnosed with fistulas. The 30-day mortality following perforation was 50%, with 30% of patients dying within 1 week. Patients with rectovaginal nodularity were more likely to develop a bowel perforation or fistula than those who did not have this finding, OR = 3.64 (95% CI = 1.1 to 12.1, p = 0.04). None of the other variables were significantly associated with bowel perforations or fistula formation. Conclusions.: Rectovaginal nodularity is associated with an increased risk of bowel perforation or fistula formation for patients with recurrent EOC treated with bevacizumab. Careful consideration should be given prior to initiating bevacizumab treatment in EOC patients with rectovaginal nodularity since the mortality rate with bevacizumab associated bowel perforations is 50%.

Original languageEnglish (US)
Pages (from-to)47-51
Number of pages5
JournalGynecologic Oncology
Volume118
Issue number1
DOIs
StatePublished - Jul 2010

Fingerprint

Fistula
Bevacizumab
Ovarian epithelial cancer
Mortality
Logistic Models
Drug Therapy
Therapeutics

Keywords

  • Bevacizumab
  • Bowel perforation
  • Epithelial ovarian cancer
  • Fistula
  • Risk factors

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? / Richardson, D. L.; Backes, F. J.; Hurt, J. D.; Seamon, L. G.; Copeland, L. J.; Fowler, J. M.; Cohn, D. E.; O'Malley, D. M.

In: Gynecologic Oncology, Vol. 118, No. 1, 07.2010, p. 47-51.

Research output: Contribution to journalArticle

Richardson, D. L. ; Backes, F. J. ; Hurt, J. D. ; Seamon, L. G. ; Copeland, L. J. ; Fowler, J. M. ; Cohn, D. E. ; O'Malley, D. M. / Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?. In: Gynecologic Oncology. 2010 ; Vol. 118, No. 1. pp. 47-51.
@article{758c9d97ec444cb991c6074638fc9edf,
title = "Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?",
abstract = "Background.: Increased rates of bowel perforation in patients with recurrent epithelial ovarian cancer (EOC) treated with bevacizumab have been reported, but the risk factors for this association are uncertain. We sought to identify factors associated with bowel perforation and fistula formation in recurrent EOC patients treated with bevacizumab. Methods.: A chart review of all patients treated with bevacizumab for recurrent EOC at a single institution was performed. Pertinent patient characteristics and treatment information were collected. Univariate logistic regression was performed to analyze multiple variables. Results.: One hundred twelve patients who were treated with 160 different bevacizumab regimens were identified. The median age was 60 years (range, 29-78 years). Patients had received a median of 4 prior chemotherapy regimens (range, 1-10). The median number of cycles was 4 (range, 0.5-31). Ten patients (9{\%}) were diagnosed with bowel perforations, and another 2 patients (1.8{\%}) were diagnosed with fistulas. The 30-day mortality following perforation was 50{\%}, with 30{\%} of patients dying within 1 week. Patients with rectovaginal nodularity were more likely to develop a bowel perforation or fistula than those who did not have this finding, OR = 3.64 (95{\%} CI = 1.1 to 12.1, p = 0.04). None of the other variables were significantly associated with bowel perforations or fistula formation. Conclusions.: Rectovaginal nodularity is associated with an increased risk of bowel perforation or fistula formation for patients with recurrent EOC treated with bevacizumab. Careful consideration should be given prior to initiating bevacizumab treatment in EOC patients with rectovaginal nodularity since the mortality rate with bevacizumab associated bowel perforations is 50{\%}.",
keywords = "Bevacizumab, Bowel perforation, Epithelial ovarian cancer, Fistula, Risk factors",
author = "Richardson, {D. L.} and Backes, {F. J.} and Hurt, {J. D.} and Seamon, {L. G.} and Copeland, {L. J.} and Fowler, {J. M.} and Cohn, {D. E.} and O'Malley, {D. M.}",
year = "2010",
month = "7",
doi = "10.1016/j.ygyno.2010.01.011",
language = "English (US)",
volume = "118",
pages = "47--51",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

AU - Richardson, D. L.

AU - Backes, F. J.

AU - Hurt, J. D.

AU - Seamon, L. G.

AU - Copeland, L. J.

AU - Fowler, J. M.

AU - Cohn, D. E.

AU - O'Malley, D. M.

PY - 2010/7

Y1 - 2010/7

N2 - Background.: Increased rates of bowel perforation in patients with recurrent epithelial ovarian cancer (EOC) treated with bevacizumab have been reported, but the risk factors for this association are uncertain. We sought to identify factors associated with bowel perforation and fistula formation in recurrent EOC patients treated with bevacizumab. Methods.: A chart review of all patients treated with bevacizumab for recurrent EOC at a single institution was performed. Pertinent patient characteristics and treatment information were collected. Univariate logistic regression was performed to analyze multiple variables. Results.: One hundred twelve patients who were treated with 160 different bevacizumab regimens were identified. The median age was 60 years (range, 29-78 years). Patients had received a median of 4 prior chemotherapy regimens (range, 1-10). The median number of cycles was 4 (range, 0.5-31). Ten patients (9%) were diagnosed with bowel perforations, and another 2 patients (1.8%) were diagnosed with fistulas. The 30-day mortality following perforation was 50%, with 30% of patients dying within 1 week. Patients with rectovaginal nodularity were more likely to develop a bowel perforation or fistula than those who did not have this finding, OR = 3.64 (95% CI = 1.1 to 12.1, p = 0.04). None of the other variables were significantly associated with bowel perforations or fistula formation. Conclusions.: Rectovaginal nodularity is associated with an increased risk of bowel perforation or fistula formation for patients with recurrent EOC treated with bevacizumab. Careful consideration should be given prior to initiating bevacizumab treatment in EOC patients with rectovaginal nodularity since the mortality rate with bevacizumab associated bowel perforations is 50%.

AB - Background.: Increased rates of bowel perforation in patients with recurrent epithelial ovarian cancer (EOC) treated with bevacizumab have been reported, but the risk factors for this association are uncertain. We sought to identify factors associated with bowel perforation and fistula formation in recurrent EOC patients treated with bevacizumab. Methods.: A chart review of all patients treated with bevacizumab for recurrent EOC at a single institution was performed. Pertinent patient characteristics and treatment information were collected. Univariate logistic regression was performed to analyze multiple variables. Results.: One hundred twelve patients who were treated with 160 different bevacizumab regimens were identified. The median age was 60 years (range, 29-78 years). Patients had received a median of 4 prior chemotherapy regimens (range, 1-10). The median number of cycles was 4 (range, 0.5-31). Ten patients (9%) were diagnosed with bowel perforations, and another 2 patients (1.8%) were diagnosed with fistulas. The 30-day mortality following perforation was 50%, with 30% of patients dying within 1 week. Patients with rectovaginal nodularity were more likely to develop a bowel perforation or fistula than those who did not have this finding, OR = 3.64 (95% CI = 1.1 to 12.1, p = 0.04). None of the other variables were significantly associated with bowel perforations or fistula formation. Conclusions.: Rectovaginal nodularity is associated with an increased risk of bowel perforation or fistula formation for patients with recurrent EOC treated with bevacizumab. Careful consideration should be given prior to initiating bevacizumab treatment in EOC patients with rectovaginal nodularity since the mortality rate with bevacizumab associated bowel perforations is 50%.

KW - Bevacizumab

KW - Bowel perforation

KW - Epithelial ovarian cancer

KW - Fistula

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=77953290179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953290179&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2010.01.011

DO - 10.1016/j.ygyno.2010.01.011

M3 - Article

C2 - 20382413

AN - SCOPUS:77953290179

VL - 118

SP - 47

EP - 51

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -